The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies.
 
Daneng Li
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Merck; Sumitomo Pharma Oncology; Tersera; TransThera Biosciences
Speakers' Bureau - Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst); Brooklyn ImmunoTherapeutics (Inst)
 
Anthony F. Shields
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbisko Therapeutics (Inst); Alkermes; Amal Therapeutics (Inst); Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; Gritstone Bio (Inst); H3 Biomedicine; Halozyme; Hutchison China Meditech; IconOVir Bio (Inst); ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Nuvation Bio (Inst); Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Hirva Mamdani
Consulting or Advisory Role - AstraZeneca; Genentech; MorphoSys (I); Seagen (I); Zentalis
 
Jennifer Leddon
No Relationships to Disclose
 
Patrick M. Travis
No Relationships to Disclose
 
Colt A. Egelston
No Relationships to Disclose
 
Oscar Colunga Flores
No Relationships to Disclose
 
Stanley R. Hamilton
Research Funding - CytoImmune Therapeutics (Inst); Intima (Inst); Iovance Biotherapeutics (Inst); Minerva Biotechnologies (Inst)
 
Janet Austria
No Relationships to Disclose
 
Amanda Seiz
Employment - Imugene
Stock and Other Ownership Interests - Imugene
Consulting or Advisory Role - IAA Consulting
 
Sharon Yavrom
Employment - Imugene
Stock and Other Ownership Interests - Imugene
 
John Chong Han Byon
Employment - Imugene; Seagen (I)
Stock and Other Ownership Interests - Fate Therapeutics; Imugene; Seagen (I)
Consulting or Advisory Role - CARGO Therapeutics
Travel, Accommodations, Expenses - Fate Therapeutics; Imugene; Seagen (I)
 
Paul Paul Woodard
Employment - Immune-Onc Therapeutics; Imugene
Leadership - Immune-Onc Therapeutics; Imugene
Stock and Other Ownership Interests - Immune-Onc Therapeutics
Patents, Royalties, Other Intellectual Property - 1. Patent application for use of atezolizumab + talimogene lahereparepvec in triple negative breast cancer.
Travel, Accommodations, Expenses - Immune-Onc Therapeutics; Imugene
 
Grey A Wilkinson
Employment - Imugene; Merck
Patents, Royalties, Other Intellectual Property - Oncolytics